Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Amgen to reduce price...

    Amgen to reduce price of its cholesterol drug Repatha starting 2020

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-03T09:15:14+05:30  |  Updated On 16 Aug 2021 2:25 PM IST

    Amgen launched the lower-price option of Repatha last October, selling the drug to some patients under the list price of $5,850 per year because the drug's original $14,000-year-list price was too much for many patients in Medicare or with high-deductible plans.


    New Delhi: Drugmaker Amgen Inc said on Thursday that starting next year, its official list price for cholesterol drug Repatha will be the lower price it began offering last year to patients on Medicare and those paying for the drug out-of-pocket.


    The company launched the lower-price option last October, selling the drug to some patients under the list price of $5,850 per year because the drug's original $14,000-year-list price was too much for many patients in Medicare or with high-deductible plans.


    But Amgen still sold the drug under its original list price, because it had already negotiated discounts in contracts with payers like pharmacy benefit managers (PBMs) based on that price. At the time, Amgen said $5,850 was in line with what most patients with private insurance were paying for the drug after discounts and rebates.


    They said then that they planned on discontinuing the original list price of Repatha by the end of 2020 or sooner.


    The list price for drugs is not necessarily what patients actually pay as "out-of-pocket" costs vary based on the duration of the treatment and individual healthcare plans.


    Read Also: Amgen drug AMG510 shrinks lung cancer tumours in half of the patients in an early-stage trial


    Amgen said that the cost for patients covered under its current contracts with PBMs and health plans will pay $5,850 a year or less for Repatha.


    It said that standardizing the lower-price option will help because some Medicare patients' prescription drug plans were not able to buy the drug under the lower list price option.


    Sales of drugs like Repatha that dramatically lower bad LDL cholesterol by targeting the PCSK9 protein have been constrained by insurers looking to limit spending on the expensive drugs, which compete with cheap statins that cost hundreds of dollars per year.


    Read Also: Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court

    Amgencholesterolcholesterol drugdrug priceHealthcareLDLmedicarePCSK9pharmapharma companypharma newsRepatha®
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok